Abstract Janus kinase 2 (JAK2) hyperactivation by JAK2V617F mutation leads to myeloproliferative neoplasms (MPNs) and targeting JAK2 could serve as a promising therapeutic strategy for MPNs. Here, we report that Flonoltinib Maleate (FM), a selective JAK2/FLT3 inhibitor, shows high selectivity for JAK2 over the JAK family. Surface plasmon resonance assays verified that FM had a stronger affinity […]
Breaking news on Celgene’s Fedratinib for Myelofibrosis patients!
by David Wallace Fedratinib by Celgene, offered on Expanded Access Program (EAP) for Myelofibrosis Patients This is hot off the press! So hot, that no one has covered it until now – brought to you by PV Reporter. I knew after combing through the ASH (American Society of Hematology) abstracts that something was missing. That […]
